Practical Management of Cardiovascular Adverse Events with BTKi
Treatment in Patients with Chronic Lymphocytic Leukemia: A
Consensus Report by Hematologists and Cardiologists

J 2026

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists

MUNIR, Talha; Egle CIBURIENE; Vasko GRAKLANOV; Mariana GOSPODINOVA; Ozren JAKSIC et al.

Základní údaje

Originální název

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists

Autoři

Vydání

Acta Haematologica, BASEL, KARGER, 2026, 0001-5792

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.100 v roce 2024

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Bruton's tyrosine kinase inhibitors; Chronic lymphocytic leukemia; Cardiovascular adverse events; Ibrutinib

Štítky

14110212

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 3. 2026 11:51, Mgr. Tereza Miškechová

Anotace

V originále

Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton's tyrosine kinase inhibitors (BTKis). Although these AEs are managed effectively in most cases and AE management guidelines exist, practical management approaches are inconsistent across regions and practices. We aimed to address these inconsistencies by developing consensus recommendations. Summary: A European expert panel was assembled comprising eight hematologists and six cardiologists. Literature analysis, expert interviews, and the Delphi method were used to gain consensus on screening, monitoring, and treatment of AF and hypertension statements. Key Messages: Maintaining BTKi treatment is paramount to maximize time to next treatment; for patients at high risk of progression, this can be achieved by appropriately treating hypertension and AF and adjusting the BTKi dose. Patients should be risk-stratified as low, moderate, high, or very-high risk of cancer therapy-related CV toxicity and treated according to their disease status so that CLL treatment can be maintained. Patient education on symptom monitoring, home blood pressure monitoring, and electrocardiograms (baseline, every 3 months) are recommended to detect/monitor AF and hypertension. Close collaboration between hematologists and cardiologists is vital to achieve optimal patient outcomes.

Citovat

MUNIR, Talha; Egle CIBURIENE; Vasko GRAKLANOV; Mariana GOSPODINOVA; Ozren JAKSIC; Luka LIPAR; Imelda MARTON; Anna PANOVSKÁ; Lucia PETRIKOVA; Regina PILECKYTE; Zoltan POZSONYI; Miroslav SLANINA; Matevz SKERGET a Nikola BULJ. Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. Acta Haematologica. BASEL: KARGER, 2026, 16 s. ISSN 0001-5792. Dostupné z: https://doi.org/10.1159/000547426.

@article{2558037,
   author = {Munir, Talha and Ciburiene, Egle and Graklanov, Vasko and Gospodinova, Mariana and Jaksic, Ozren and Lipar, Luka and Marton, Imelda and Panovská, Anna and Petrikova, Lucia and Pileckyte, Regina and Pozsonyi, Zoltan and Slanina, Miroslav and Skerget, Matevz and Bulj, Nikola},
   article_location = {BASEL},
   doi = {https://doi.org/10.1159/000547426},
   keywords = {Bruton's tyrosine kinase inhibitors; Chronic lymphocytic leukemia; Cardiovascular adverse events; Ibrutinib},
   language = {eng},
   issn = {0001-5792},
   journal = {Acta Haematologica},
   title = {Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists},
   url = {https://karger.com/aha/article/doi/10.1159/000547426/930715/Practical-Management-of-Cardiovascular-Adverse},
   year = {2026}
}

TY  - JOUR
ID  - 2558037
AU  - Munir, Talha - Ciburiene, Egle - Graklanov, Vasko - Gospodinova, Mariana - Jaksic, Ozren - Lipar, Luka - Marton, Imelda - Panovská, Anna - Petrikova, Lucia - Pileckyte, Regina - Pozsonyi, Zoltan - Slanina, Miroslav - Skerget, Matevz - Bulj, Nikola
PY  - 2026
TI  - Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists
JF  - Acta Haematologica
PB  - KARGER
SN  - 00015792
KW  - Bruton's tyrosine kinase inhibitors
KW  - Chronic lymphocytic leukemia
KW  - Cardiovascular adverse events
KW  - Ibrutinib
UR  - https://karger.com/aha/article/doi/10.1159/000547426/930715/Practical-Management-of-Cardiovascular-Adverse
N2  - Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton's tyrosine kinase inhibitors (BTKis). Although these AEs are managed effectively in most cases and AE management guidelines exist, practical management approaches are inconsistent across regions and practices. We aimed to address these inconsistencies by developing consensus recommendations. Summary: A European expert panel was assembled comprising eight hematologists and six cardiologists. Literature analysis, expert interviews, and the Delphi method were used to gain consensus on screening, monitoring, and treatment of AF and hypertension statements. Key Messages: Maintaining BTKi treatment is paramount to maximize time to next treatment; for patients at high risk of progression, this can be achieved by appropriately treating hypertension and AF and adjusting the BTKi dose. Patients should be risk-stratified as low, moderate, high, or very-high risk of cancer therapy-related CV toxicity and treated according to their disease status so that CLL treatment can be maintained. Patient education on symptom monitoring, home blood pressure monitoring, and electrocardiograms (baseline, every 3 months) are recommended to detect/monitor AF and hypertension. Close collaboration between hematologists and cardiologists is vital to achieve optimal patient outcomes.
ER  -

MUNIR, Talha; Egle CIBURIENE; Vasko GRAKLANOV; Mariana GOSPODINOVA; Ozren JAKSIC; Luka LIPAR; Imelda MARTON; Anna PANOVSKÁ; Lucia PETRIKOVA; Regina PILECKYTE; Zoltan POZSONYI; Miroslav SLANINA; Matevz SKERGET a Nikola BULJ. Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. \textit{Acta Haematologica}. BASEL: KARGER, 2026, 16 s. ISSN~0001-5792. Dostupné z: https://doi.org/10.1159/000547426.

Přehled o publikaci